Rheumatoid Arthritis (RA) Clinical Trials

Find Rheumatoid Arthritis (RA) Clinical Trials Near You

Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This study will be a randomized controlled parallel study that will be conducted on 66 patients with active rheumatoid arthritis who will be diagnosed with RA according to American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR, 2010). The patients will be recruited from Outpatient Clinic of Rheumatology, Physical Medicine, Rheumatology and Rehabilitation Department, Tanta University Hospital, Tanta, Egypt. The study duration will be 3 months. The patients will be randomized into three groups: \- Group 1 (control group): will include 22 patients who will receive the conventional therapy for RA for 3 months. \- Group 2 (diosmin group): will include 22 patients who will receive the conventional therapy for RA plus 1000 mg diosmin once daily for 3 months. \- Group 3 (rebamipide group): will include 22 patients who will receive the conventional therapy for RA plus 100 mg rebamipide three times daily for 3 months.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR). i.e.,28 joints disease activity score (DAS-28) \>2.6.

• Both sexes.

• Age ranges between 18 and 70 years old.

• Patients receiving conventional DMARDs

Locations
Other Locations
Egypt
Faculty of Pharmacy Tanta University
RECRUITING
Tanta
Contact Information
Primary
khlood mohamed kettana, assistant lecturer
khlood.kettana@pharm.tanta.edu.eg
01091100037
Time Frame
Start Date: 2026-08-01
Estimated Completion Date: 2027-08-01
Participants
Target number of participants: 66
Treatments
Active_comparator: Group 1 (control group):
will include 22 patients who will receive the conventional therapy for RA for 3 months.
Active_comparator: Group 2 (diosmin group):
will include 22 patients who will receive the conventional therapy for RA plus 1000 mg diosmin once daily for 3 months.
Active_comparator: Group 3 (rebamipide group):
will include 22 patients who will receive the conventional therapy for RA plus 100 mg rebamipide three times daily for 3 months.
Related Therapeutic Areas
Sponsors
Leads: Tanta University

This content was sourced from clinicaltrials.gov